Glecaprevir – pibrentasvir is the first pangenotypic NS3/ 4A protease inhibitor- NS5A inhibitor combination is a better option to cure the chronic hepatitis C as it gives majority of patients a ribavirin free option unlike the other medicines. The drug is not suitable for the patients with decompensated cirrhosis because of the presence of the protease inhibitor. Clinical reports have shown 98-100% positive response rate amongst patients with genotypes 1, 2, 5 and 6. This is the least expensive treatment of Hepatitis C with lesser side effects.